The Efficacy and Safety of JS002 PFS and AI in Patients With Primary Hypercholesterolemia and Mixed Hyperlipidemia

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 255 participants.

Also called NCT05532800

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 255 participants (enrolled count) (from the registry)
Sponsor
Shanghai Junshi Bioscience Co., Ltd. (from the registry)
Registry
  • NCT NCT05532800
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05532800. Randomized; quadruple masking; primary purpose treatment. Start 2022-02-28 (actual); primary completion 2023-02-09 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
The Efficacy and Safety of JS002 PFS and AI in Patients With Primary Hypercholesterolemia and Mixed Hyperlipidemia
Condition
Hyperlipemia
Intervention (Drug)
JS002
Intervention (Drug)
Placebo
Lead sponsor
Shanghai Junshi Bioscience Co., Ltd. (class: other)

Record details

Record id
cardio:ct-nct05532800
Content hash
4f208eb5029ac36c7de054a4a2c9acfbe33e77b7a6882d1e72d557b4cdf9103a